Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MRVI - MARAVAI LIFESCIENCES HOLDINGS, INC.


IEX Last Trade
5.46
-0.005   -0.092%

Share volume: 9,859
Last Updated: Fri 27 Dec 2024 08:30:26 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.90%

PREVIOUS CLOSE
CHG
CHG%

$5.46
0.00
-0.09%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
24%
Profitability 14%
Dept financing 23%
Liquidity 75%
Performance 20%
Company vs Stock growth
vs
Performance
5 Days
9.36%
1 Month
-5.24%
3 Months
-33.37%
6 Months
-20.76%
1 Year
-15.77%
2 Year
-59.41%
Key data
Stock price
$5.46
P/E Ratio 
-9.70
DAY RANGE
$5.38 - $5.60
EPS 
-$0.99
52 WEEK RANGE
$4.65 - $11.55
52 WEEK CHANGE
-$14.35
MARKET CAP 
1.281 B
YIELD 
N/A
SHARES OUTSTANDING 
141.553 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.71
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,693,806
AVERAGE 30 VOLUME 
$1,575,534
Company detail
CEO: Carl W. Hull
Region: US
Website: maravai.com
Employees: 610
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Maravai LifeSciences Holdings, Inc. provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics.

Recent news